Susan Treacy
CEO, HealthTech Ireland
Innovation in healthcare can mean many things. One practical way to understand its impact is through time: time to diagnosis, time waiting for decisions, time in the system, and time spent at home with the right support.
With rising demand, workforce pressures and increasing complexity, time is constrained, making it one of the clearest lenses through which innovation can deliver real benefit.
In practice, this looks different for each patient. For someone with a rare disease, it can mean connected data across hospital, community and palliative services, reducing repetition and enabling more coordinated care. For others, it is assistive technology that supports independence or enables remote care at home. Elsewhere, improved diagnostics help clinicians focus on patients who need attention most.
These innovations are not theoretical; many are proven in Ireland and internationally. Yet, they are not yet consistently embedded in everyday care.
Ireland has many of the right ingredients
Strong collaboration between clinicians, patient groups and industry. National strategies set clear direction, alongside enabling developments including the Health Information Bill and EHDS.
A key component of meeting future healthcare challenges, and ensuring Europe remains globally competitive, is effective AI application as part of this broader innovation ecosystem. Applied well, AI can support earlier diagnosis, smarter resource allocation and more proactive care, while reducing administrative burden.
This challenge is playing out in Europe and at home. At the recent MedTech Forum in Stockholm, the urgency for Europe to strengthen its innovation competitiveness was clear. The European Commission recognised the need for a more innovation-friendly environment, including the impact of regulatory complexity and the need for procurement reform to better enable access to innovation.
This comes against a shifting geopolitical backdrop, where resilience, strategic autonomy and the ability for innovation scalability within Europe are increasingly important.
improved diagnostics help clinicians focus on patients who need attention most
Ireland’s life sciences strategy
In Ireland, critical work is underway on a Life Sciences Strategy, informed through engagement across DETE and the DoH, supported by insights from HealthTech Ireland and others. It reflects a shared ambition to better connect innovation across data, diagnostics, devices and medicines with patient care.
Through HealthTech Ireland, and in collaboration with the HSE, hospitals, HIQA and the National Health Collaboration Council, there is strong commitment across the system, alongside a robust national healthtech and life sciences base with engaged patient and clinical communities. Translating this into direct value requires delivery at pace and at scale.
Turning intent into practice
The focus is now firmly on implementation, creating clearer pathways to adopt what is already proven and supporting services to embed it in day-to-day care. The HSE national innovation framework, released recently and ongoing cross-sector work for an implementation plan, will enable delivery. All of this is critical to building structure and clarity around how innovation is brought into routine use.
With the EU Presidency too and associated events with HealthTech Ireland, there is a real opportunity to better align strategy, procurement and frontline delivery, moving innovation consistently into practice. Done well, this can reduce administrative burden, support clinical teams and enable earlier, more proactive care.
At a time of sustained system pressure, the urgency is clear. Innovation is not in short supply. The priority is implementation, ensuring that what already exists reaches patients consistently and becomes standard practice.
